江苏集萃药康生物科技股份有限公司Gempharmatech Co., Ltd于2022年12月告诉投资者说：它的美国子公司已在 Boston 和 San Diego 设立办公室，美国生产设施的设立已提上日程，目前正在进行地点选择和财务测算。江苏集萃药康生物科技股份有限公司Gempharmatech Co., Ltd在美国的子公司为GemPharmatech LLC （中文名：集萃药康公司），持股比例100%。2022上半年江苏集萃药康生物科技股份有限公司增加对美国子公司GemPharmatech LLC的投资1759.34万人民币元，累计投资3730.82万人民币元。江苏集萃药康生物科技股份有限公司是中共军队第二军医大学既海军军医大学的供应商。美国企业Sigma、 CST、ThermoFisher也是中共军队第二军医大学的供应商。Gempharmatech Co., Ltd,a supplier to PLA 2nd Military Medical University, told investors in Dec 2022 that 100% owned US subsidiary GemPharmatech LLC set up offices in Boston and San Diego. US production facilities setup has been on agenda, for which site selection, as well as financial calculation, is underway.In the first half of 2022, Gempharmatech Co., Ltd increased its investment in GemPharmatech LLC by RMB 17.5934 million, with a total investment of RMB 37.3082 million. Genor Biopharma Holdings Limited, Genor Biopharma (HK) Limited and ZHAOKE OPHTHALMOLOGY LIMITED are related parties to Gempharmatech Co., Ltd. Sigma, CST, and ThermoFisher, Companies from the United States, are also suppliers to the Second Military Medical University of the Chinese Communist Army.
江苏集萃药康生物科技股份有限公司是中共陆军军医大学（第三军医大学）的供应商。Gempharmatech Co., Ltd is also a supplier to the 3rd Military Medical University or Army Medical University of the Chinese Communist Party's military force PLA.
与中国科学院关系紧密的上海南方模式生物科技股份有限公司Shanghai Model Organisms Center, Inc已取得上海市浦东新区发改委出具的境外投资项目备案通知书和上海市商务委员会派发的企业境外投资证书，将通过对美国子公司增资在美国建立动物设施和动物实验技术服务团队，服务中共的生物武器计划。Shanghai Model Organisms Center, Inc, which has a close relationship with the Chinese Academy of Sciences, has obtained the Notification of Overseas Investment Project Filed issued by the Shanghai Pudong New Area Development and Reform Commission and the Enterprise Overseas Investment Certificate issued by the Shanghai Municipal Commission of Commerce. It is to increase capital of its US subsidiary to establish animal facilities and animal experiment technical service teams in the United States to serve the CCP's bioweapon program.
上海南方模式生物科技股份有限公司在美国的子公司叫上海模式生物中心（美国）有限公司Shanghai Model Organisms Center (USA) LLC。上海南方模式生物科技股份有限公司 2022 年6月30日总人数为 562 人，较 2021 年末增 加 53 人，增长10.41%，计算过程：53/（562-53）×100%。The subsidiary in the USA of Shanghai Model Organisms Center, Inc, a supplier of Academy of Military Medical Sciences of Chinese People's Liberation Army ie Chinese Communist military force, is called Shanghai Model Organisms Center (USA) LLC. The total number of people in Shanghai Model Organisms Center, Inc on 30 June 2022 is 562, increase of 53 or 10.41% over 31 Dec 2021.
上海南方模式生物科技股份有限公司向中共军队的军事医学科学院提供服务的记录。Record of Shanghai Model Organisms Center, Inc delivering services to Academy of Military Medical Sciences of the Chinese Communist Party's military force PLA.
上海南方模式生物科技股份有限公司向中共空军军医大学、陆军军医大学、武警的部分发货记录。Record on Shanghai Model Organisms Center, Inc delivering solutions to Air Force Medical University, Army Medical University and Armed Police of CCP's military force PLA. Be careful. The date format of China, yyyy/mm/dd, is different from other parts of world,such as dd/mm/yyyy or mm/dd/yyyy. The amount format of China, RMB'0,000 ie RMB 10 thousand, is different from format usually used, such as RMB'000, GBP'000, or USD'000.
尽管每股收益下降 84.85% 且经营活动所产生的现金流量净额为负数，但截至 2022 年 9 月 30 日止 9 个月，上海南模生物中心有限公司为投资支付的现金较截至 2021 年 9 月 30 日止 的9 个月增加了 12.45 倍。与2021年12月31日相比，2022年9月30日无形资产账面价值增加1020.77倍，在建工程账面价值增加7.06倍。Despite EPS decrease of 84.85% and negative operation cash flow, the cash paid for investment by Shanghai Model Organisms Center, Inc for the 9 months ended with 30 Sep 2022 increased by 12.45 times, compared with 9 months ended with 30 Sep 2021. Compared with 31st December 2021, carrying value of intangible assets increased by 1020.77 times, and carrying value of construction in progress increased by 7.06 times as of 30th September 2022.
在中国传播开来的病毒株是习近平指挥的军事医科院的军民融合体人工造出来的不同变种，由习近平指挥故意投放的。The virus strains that spread in China are different variants artificially created by the military-civilian fusion of the Academy of Military Medical Sciences commanded by Xi Jinping, and deliberately released by Xi Jinping's command.
中华人民共和国生物安全法规定国家安全委员会负责统筹和协调生物安全，即微生物实验室、生物技术研究、开发与应用等地方的安全管理问题。习近平是中共中央国家安全委员会主席、中共中央军委主席。The Biosafety Law of the People's Republic of China stipulates that the National Safety Commission is responsible for unified directing and coordinating biosafety, that is, the safety management issues of microbiology laboratories, biotechnology research, development and application, etc. Xi Jinping is the chairman of the National Security Commission and the chairman of the Central Military Commission of the Central Committee of Chinese Communist Party .
中华人民共和国生物安全法规定“（二）生物技术研究、开发与应用；（三）病原微生物实验室生物安全管理”适用《生物安全法》，于是中共中央军委主席习近平利用中央国家安全委员会主席的职务便利在“生物技术研究、开发与应用”的名义下操纵整个中华人民共和国的机构服务于传染病、毒药、细菌的研发、制造、投放。The Biosafety Law of the People's Republic of China stipulates that "(2) biotechnology research, development and application; (3) biosafety management of pathogenic microorganism laboratories" should be subject to provisions in the "Biosafety Law", so Xi Jinping, chairman of the Central Military Commission of Chinese Communist Party of China, used the position, chairman of the Central National Security Commission's convenience to manipulate the institutions of the entire People's Republic of China under the name of "biotechnology research, development and application" to serve the research and development, manufacture and distribution of infectious diseases, poisons and bacteria.
参与中国共产党传染病、毒药、细菌的研发、制造、投放即所谓的“生物技术研究、开发与应用”同时有病原微生物实验室的机构包括但不限于军事医学科学院、中国科学院、第三军医大学、第二军医大学、北京大学等。Institutions that participate in the research, development, manufacture, and delivery of infectious diseases, poisons, and bacteria of the Chinese Communist Party, the so-called "biotechnology research, development, and application," and that also have pathogenic microorganism laboratories include but are not limited to the Academy of Military Medical Sciences, the Chinese Academy of Sciences, and the Third Military Medical University. , Second Military Medical University, Peking University, etc.
